JP4053559B2 - 過活動膀胱を治療するための治療剤 - Google Patents
過活動膀胱を治療するための治療剤 Download PDFInfo
- Publication number
- JP4053559B2 JP4053559B2 JP2005331664A JP2005331664A JP4053559B2 JP 4053559 B2 JP4053559 B2 JP 4053559B2 JP 2005331664 A JP2005331664 A JP 2005331664A JP 2005331664 A JP2005331664 A JP 2005331664A JP 4053559 B2 JP4053559 B2 JP 4053559B2
- Authority
- JP
- Japan
- Prior art keywords
- prostate
- therapeutic agent
- patient
- bladder
- botulinum toxin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Marine Sciences & Fisheries (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Reproductive Health (AREA)
- Cardiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
請求項5に記載の発明は、請求項2に記載の治療剤において、該治療剤は患者の膀胱頸部に投与するのに適した剤型にて提供されることをその要旨とする。
請求項6に記載の発明は、請求項2に記載の治療剤において、該治療剤は患者の膀胱壁に投与するのに適した剤型にて提供されることをその要旨とする。
請求項7に記載の発明は、請求項1に記載の治療剤において、該頻尿は夜間頻尿を含むことをその要旨とする。
光学顕微鏡のための組織調製
組織を、0.1Mリン酸緩衝液pH7.2中の6%パラホルムアルデヒドで24時間固定し、等級の高いアルコールとキシレン中で脱水し、パラフィン中に包埋する。切片を切断して取り、ヘマトキシリン/エオシンなどの適切な染色剤で染色する。
組織を集め、0.1Mリン酸緩衝液pH7.2中の2.5%グルタルアルデヒド中で、4℃、1時間固定し、次いで、0.1%四酸化オスミニウムで1時間インキュベートし、EPON中に包埋する。超薄片(80nm)を調製し、クエン酸鉛/酢酸ウラニルで染色し、電子顕微鏡(Philips,モデル201)で検査する。
組織を、上記のように固定し、包埋する。組織を脱パラフィンし、プロテイナーゼK(Boehringer)と反応させる。それらを更に、ペルオキシダーゼとTDT酵素で処理し、37℃にセットされた加湿器中に1時間入れる。切片を洗浄し、抗ジゴキシゲニン−ペルオキシダーゼを30分間加え、次いで、ニッケル−DAB(ジアミノベンゼン)で染色を行う。
神経ペプチドであるVIP、SP、NPY、L−Enk、及びカルシトニン遺伝子関連ペプチド(CGRP)の存在、並びにトランスフォーミング成長因子β(TGF−β)、トランスフォーミング成長因子α(TGF−α)、上皮成長因子(EGF)及び塩基性繊維芽細胞成長因子(bFGF)の発現を、適切なモノクローナル抗体を用いて、前立腺組織で測定する。神経毒の使用により前立腺が萎縮し、それは、処理された前立腺組織における低レベルの成長因子によってリネクトされる(renected)はずである。
処理した、及び未処理の前立腺細胞ホモジネートの成長因子発現を、ウエスタンブロット分析によって試験する。細胞ホモジネートタンパク質をSDS−PAGE(7%)の電気泳動で分離し、次いで、電気泳動で一晩、ニトロセルロースペーパーに移す(Towbin,H.,ら,[1979]Proc.Nat.Acad.Sci.76(9):4350−4379)。ニトロセルロースペーパーを、リン酸緩衝化生理食塩水中に溶解した0.5%無脂肪乾燥ミルク中に1時間、室温で浸し、更にブッロキング溶液(10mM Tris/0.15M NaCl/0.1%アジ化ナトリウム,pH7.4中2%ウシ血清アルブミン)中で一晩、4℃で浸す。ニトロセルロース膜をブッロキング緩衝液中で1時間、プロテインAで精製した抗体(抗TGF−β、抗TGF−α、抗EGF、抗bFGFのIgG分画)(1×106cpm/mL)とインキュベートする。膜をインキュベーションの間に、Nonidet P−40を含有するPBSで洗浄する。X−O−mat AR2 フィルム(Kodak)を−70℃で膜に曝し、フィルムを現像し、成長因子の発現を試験する。
処理した、及び未処理の前立腺組織のc−fosとc−mycの発現を以下のようにノーザンブロット分析で測定する。組織を、15秒間又は組織がホモゲナイズされるまで、溶解緩衝液中でホモゲナイズする。酢酸ナトリウムを加え、溶液に渦巻きを起こさせて混合する。等量の水飽和フェノールを加え、逆さにして混合し、次いでクロロホルム/イソアミルアルコールを加える。溶液に30秒間激しく渦を巻かせ、15分間氷上に放置する。溶液を4℃で10−20分間遠心する。遠心後、水相を注意深く吸引し、新しいポリプロピレンチューブに入れる。一体積のイソプロパノールを加え、溶液を渦巻きによって混合する。溶液を最低60分間−20℃フリーザーに入れ、RNAを沈殿させる。沈殿後、チューブを10分間遠心し、上清をデカントで捨て、RNAペレットを残す。1mLのエタノールを加え、チューブを更に10分間遠心する。水相を捨て、ペレットを渦巻きによって100%エタノールで洗浄する。RNAペレットを溶解緩衝液0.4mLで再溶解する。RNAに100%エタノールを添加し、最低60分間−20℃フリーザーでインキュベーションすることにより再沈殿させる。溶液を遠心し、上清を捨てる。サンプル5μLをDEPC水995μL中に希釈し、260/280nmでの吸光度の比を測定することにより、RNA濃度を測定する。
前立腺の片側性脱神経は、ラットの前立腺に重層する骨盤神経節の除去によって行う。この方法により、膀胱と尿道後部の機能的完全性は保存され、血流又は放尿における、主要な乱れから起るアーティファクトの可能性が除かれる。対照動物は、同時の前立腺脱神経無くして偽の手術を受ける。脱神経後、動物を回復させ、維持し、次いで前立腺を集める。前立腺を保存し、光学顕微鏡用に調製し、組織学的に検査する。主要な知見は以下のようである。(1)主に鮮明な核上帯の減少による上皮細胞高さの減少(先端槽(apical cisternae)と小胞体の量と大きさの減少によって)、(2)SDSゲル電気泳動でのタンパク質発現の主要な変化(小胞体はタンパク質合成において重要である)、(3)分泌顆粒の数の中程度の減少、(4)細胞内液胞、細胞内空空間の増加と、細胞表面の微絨毛の減少、(5)対照群に対し脱神経と同側の神経成長因子(NGF)含量の顕著な増加(188±10対46±20対29±16pg/g湿組織(±SD))。NGFは、交感神経と感覚神経のみに影響を与えることが知られている。対照群と実験群の両方でN=15。
ラットを無作為に3群に割り振った。第1群は、ボツリヌス毒素A型(Botox,Allergen)5、10、又は15IUの単一急性投与を受けた。これらの動物を注射の1週間後に殺した。第2群は、一連の週毎のボツリヌス毒素5IUの4週間投与を受け、5週目で殺した。対照ラットは生理食塩水注射を受けた。注射は、前立腺の左及び/右腹部葉中への単一又は連続注射として行った。ラット前立腺の一葉中へのメチレンブルーの注射は反対側の葉中への即時の拡散を示したことに注意せよ。即ち、前立腺葉間の伝達があり、従って、反対側の側面葉は、真の比較対照として使用できなかった。
不応性の排尿機能異常の3人の患者は、次のようにボツリヌス毒素(Botox)の注射によって処置した。患者1は47歳の男性であり、頚椎の傷害(レベルC6−C7)から二次的に尿意を抑制できなく、以前に14月を耐えた。示された尿力学によると、膀胱容量は30mLで、括約筋は弱かった(ピークの尿道圧は3.9kPa(40cm水)であった)。該患者は複数の薬理的治療法に失敗し、ペニスクランプ/コンドームデバイスに耐えられなかった。
ラットの前立腺腹部葉にボツリヌス毒素(Botox)の単一又は連続投与を行う。異なる時間間隔で前立腺を取得し、最小有効投与量と、時間と共に起る形態的及び生理的変化を測定する。最小有効投与量は、前立腺体積の減少を示す投与量と定義する。
神経毒と精巣由来ホルモンとに相互作用があるかどうかを決定するために、神経毒とホルモン性成分との相互作用を試験する研究を行う。睾丸切除術を受けたラット(ホルモン枯渇ラット)から得られたボツリヌス毒素処理前立腺組織と、睾丸切除術を受けなかったボツリヌス毒素処理ラットからの前立腺組織をこれらの研究で比較する。52匹の齢の同じラットを下記のように処理する。4匹の健康ラットは、麻酔誘導、前立腺露出、前立腺の左腹部葉中への0.2mL生理食塩水の注射からなる偽手術を受ける。3匹のラットは、前立腺への注射無しに両側の睾丸切除術を受ける(ホルモン枯渇対照)。5匹のラットは、睾丸切除術を受け、左腹部葉中に0.2mL生理食塩水の注射を受ける(ホルモン枯渇+手術ストレス対照)。4群のラットは、0.5IU、1.0IU、1.5IU、2.5IUのボツリヌス毒素注射のみを受ける(ホルモン完全性実験ラット)。16匹のラットは両側の睾丸切除術を受ける。これらのラットの8匹は、手術後5週で左腹部葉中に2.5IUのボツリヌス毒素の1回の注射で処理される。全てのラットを6週後殺し、取得した前立腺を、上記のように試験のために調製する。腺上皮に対する同様の萎縮効果が期待される。
良性前立腺過形成、非細菌性前立腺炎、前立腺痛の患者を、ボツリヌス毒素処置の前と後の両方で研究する。患者が年齢40−80歳でBPHであるか、又は25−60歳で、非細菌性前立腺炎か前立腺痛と診断されているならば、その患者は本研究に含めるのに適格である。好適な患者は、良き手術候補者ではない患者である。処置前に、患者を、前立腺特異的抗原(PSA)レベルの測定、尿力学パラメーターの評価(膀胱内圧測定図、尿道圧プロフィール、流量測定)、American Urological Association(AUA)症状スコア(Barry,M.J.,ら,[1992]J.Urol.,148:1549−1557)の測定、排尿日誌の維持、バイオプシィと共に経直腸超音波による前立腺の検査(BPH患者のみ)によって評価する。最初の評価の完了1週間後、患者に尿道鏡でボツリヌス毒素200IUを、単一片側注射、連続片側注射、又は両側注射として注射する。BPH患者は、単一注射7日後、又は連続注射5週後、TURPで処置されるか、対照TURP−バイオプシィを受ける。取得した前立腺組織を、実施例1、2、3、7−10に記載の試験のために調製する。最初の評価で試験された同一のパラメーターを用いて、患者を注射後、再評価する。
Claims (7)
- ボツリヌス毒素A型を含む治療剤であって、過活動膀胱に罹患した患者の過活動膀胱の尿意切迫及び頻尿の症状のうちの少なくとも一つを、前記患者の膀胱壁に前記治療剤を投与することにより治療する、治療剤。
- 前記治療剤は患者の膀胱に投与するのに適した剤型にて提供される請求項1に記載の治療剤。
- 前記ボツリヌス毒素A型は、液体、粉末、クリーム、エマルション、丸薬、トローチ、座薬、懸濁剤及び溶液からなる群より選択される製薬的に許容可能な製剤に処方化される請求項1又は2に記載の治療剤。
- 前記治療剤は注射可能な組成物である請求項1乃至3のいずれか一項に記載の治療剤。
- 前記治療剤は、前記患者の膀胱頸部に投与するのに適した剤型にて提供される、請求項2に記載の治療剤。
- 前記治療剤は、患者の膀胱壁に投与するのに適した剤型にて提供される、請求項2に記載の治療剤。
- 前記頻尿は夜間頻尿を含む、請求項1に記載の治療剤。
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US5258097P | 1997-07-15 | 1997-07-15 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004367500A Division JP3955061B2 (ja) | 1997-07-15 | 2004-12-20 | 泌尿器疾患を治療するための治療剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2006063089A JP2006063089A (ja) | 2006-03-09 |
JP4053559B2 true JP4053559B2 (ja) | 2008-02-27 |
Family
ID=21978526
Family Applications (9)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000502781A Expired - Lifetime JP3692033B2 (ja) | 1997-07-15 | 1998-07-15 | 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用 |
JP2004367501A Pending JP2005089479A (ja) | 1997-07-15 | 2004-12-20 | 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2004367500A Expired - Lifetime JP3955061B2 (ja) | 1997-07-15 | 2004-12-20 | 泌尿器疾患を治療するための治療剤 |
JP2005331664A Expired - Lifetime JP4053559B2 (ja) | 1997-07-15 | 2005-11-16 | 過活動膀胱を治療するための治療剤 |
JP2006002227A Pending JP2006104221A (ja) | 1997-07-15 | 2006-01-10 | 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2007002407A Expired - Lifetime JP4696082B2 (ja) | 1997-07-15 | 2007-01-10 | 脊髄損傷により二次的に起こる尿失禁の症状を治療する治療剤 |
JP2007002406A Expired - Lifetime JP4672676B2 (ja) | 1997-07-15 | 2007-01-10 | 会陰部疼痛、睾丸痛又はペニス軸の疼痛を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2008107792A Expired - Lifetime JP4815468B2 (ja) | 1997-07-15 | 2008-04-17 | 夜間睡眠時の頻繁な尿意に苦しむ患者を治療するための治療剤 |
JP2009264712A Expired - Lifetime JP5005753B2 (ja) | 1997-07-15 | 2009-11-20 | 患者の膀胱圧の上昇を低減するための、又は患者の膀胱容量を増大させるための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
Family Applications Before (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2000502781A Expired - Lifetime JP3692033B2 (ja) | 1997-07-15 | 1998-07-15 | 泌尿器疾患及び関連疾患の治療のための神経毒治療法の使用 |
JP2004367501A Pending JP2005089479A (ja) | 1997-07-15 | 2004-12-20 | 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2004367500A Expired - Lifetime JP3955061B2 (ja) | 1997-07-15 | 2004-12-20 | 泌尿器疾患を治療するための治療剤 |
Family Applications After (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2006002227A Pending JP2006104221A (ja) | 1997-07-15 | 2006-01-10 | 尿停滞を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2007002407A Expired - Lifetime JP4696082B2 (ja) | 1997-07-15 | 2007-01-10 | 脊髄損傷により二次的に起こる尿失禁の症状を治療する治療剤 |
JP2007002406A Expired - Lifetime JP4672676B2 (ja) | 1997-07-15 | 2007-01-10 | 会陰部疼痛、睾丸痛又はペニス軸の疼痛を治療するための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
JP2008107792A Expired - Lifetime JP4815468B2 (ja) | 1997-07-15 | 2008-04-17 | 夜間睡眠時の頻繁な尿意に苦しむ患者を治療するための治療剤 |
JP2009264712A Expired - Lifetime JP5005753B2 (ja) | 1997-07-15 | 2009-11-20 | 患者の膀胱圧の上昇を低減するための、又は患者の膀胱容量を増大させるための製薬組成物の調製においてボツリヌス毒素を使用する方法 |
Country Status (16)
Country | Link |
---|---|
US (5) | US6365164B1 (ja) |
EP (8) | EP1502601B2 (ja) |
JP (9) | JP3692033B2 (ja) |
KR (1) | KR100544060B1 (ja) |
CN (5) | CN1321683C (ja) |
AT (5) | ATE320815T1 (ja) |
AU (2) | AU743085B2 (ja) |
CA (5) | CA2570406C (ja) |
CY (3) | CY1105816T1 (ja) |
DE (4) | DE69833942T3 (ja) |
DK (6) | DK2145629T3 (ja) |
ES (6) | ES2336924T5 (ja) |
HK (4) | HK1064044A1 (ja) |
LU (2) | LU92055I2 (ja) |
PT (5) | PT1502601E (ja) |
WO (1) | WO1999003483A1 (ja) |
Families Citing this family (139)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
US7455845B2 (en) * | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
CA2570406C (en) | 1997-07-15 | 2012-02-14 | The Regents Of The University Of Colorado | Use of botulinum toxin for treating pelvic pain |
US7470431B2 (en) * | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
RU2242153C2 (ru) * | 1999-04-01 | 2004-12-20 | Хилинг Спортс Лимитед. | Устройство для катания на пятке и способ |
DE19925739A1 (de) * | 1999-06-07 | 2000-12-21 | Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh | Therapeutikum mit einem Botulinum-Neurotoxin |
US7838007B2 (en) * | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating mammary gland disorders |
US7838008B2 (en) | 1999-12-07 | 2010-11-23 | Allergan, Inc. | Methods for treating diverse cancers |
US6524580B1 (en) | 2000-02-15 | 2003-02-25 | Allergan Sales, Inc. | Method for treating thyroid disorders |
US6821520B2 (en) | 2000-02-15 | 2004-11-23 | Allergan, Inc. | Clostridial toxin therapy for Hashimoto's thyroiditis |
US6358513B1 (en) | 2000-02-15 | 2002-03-19 | Allergan Sales, Inc. | Method for treating Hashimoto's thyroiditis |
US6773711B2 (en) | 2000-02-15 | 2004-08-10 | Allergan, Inc. | Botulinum toxin therapy for Hashimoto's thyroiditis |
US20050214327A1 (en) * | 2000-06-02 | 2005-09-29 | Allergan, Inc. | Neurotoxin-containing suppositories and related methods |
US20040170665A1 (en) * | 2000-06-02 | 2004-09-02 | Allergan, Inc. | Intravitreal botulinum toxin implant |
US20040033241A1 (en) * | 2000-06-02 | 2004-02-19 | Allergan, Inc. | Controlled release botulinum toxin system |
US6306403B1 (en) * | 2000-06-14 | 2001-10-23 | Allergan Sales, Inc. | Method for treating parkinson's disease with a botulinum toxin |
US7491799B2 (en) * | 2000-07-21 | 2009-02-17 | Allergan, Inc. | Modified botulinum neurotoxins |
US20040219619A1 (en) * | 2000-07-21 | 2004-11-04 | Ester Fernandez-Salas | Methods of identifying compounds that alter toxin persistence and/or protease activity |
US6903187B1 (en) * | 2000-07-21 | 2005-06-07 | Allergan, Inc. | Leucine-based motif and clostridial neurotoxins |
US7691983B2 (en) | 2000-07-21 | 2010-04-06 | Allergan, Inc. | Chimera botulinum toxin type E |
GB0029125D0 (en) * | 2000-11-29 | 2001-01-10 | Specialistkliniken I Varberg H | Novel treatment |
JP4707254B2 (ja) * | 2001-04-24 | 2011-06-22 | クミアイ化学工業株式会社 | 粒状組成物及びその製造方法 |
AU2002315814B2 (en) * | 2001-07-10 | 2007-05-31 | Astellas Pharma Inc. | Medicinal composition for treatment of interstitial cystitis |
US6984375B2 (en) * | 2001-08-03 | 2006-01-10 | Allergan, Inc. | Nuclei density and nuclei area methods for determining effects of a botulinum toxin on muscles |
US20100104631A1 (en) * | 2001-08-13 | 2010-04-29 | Lipella Pharmaceuticals Inc. | Method of treatment for bladder dysfunction |
US7063860B2 (en) * | 2001-08-13 | 2006-06-20 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
US8110217B2 (en) * | 2001-08-13 | 2012-02-07 | University Of Pittsburgh | Sphingomyelin liposomes for the treatment of hyperactive bladder disorders |
US6623742B2 (en) | 2001-09-17 | 2003-09-23 | Allergan, Inc. | Methods for treating fibromyalgia |
US7255866B2 (en) | 2001-09-17 | 2007-08-14 | Allergan, Inc. | Botulinum toxin therapy for fibromyalgia |
KR20040066816A (ko) | 2001-11-15 | 2004-07-27 | 마이크로 알제 코포레이션 | 3, 4-프로피온퍼하이드로퓨린을 포함하는 약학 조성물 및상기 조성물을 이용한 신경 전달의 블로킹 방법 |
US7763663B2 (en) * | 2001-12-19 | 2010-07-27 | University Of Massachusetts | Polysaccharide-containing block copolymer particles and uses thereof |
US6688311B2 (en) | 2002-03-14 | 2004-02-10 | Allergan, Inc. | Method for determining effect of a clostridial toxin upon a muscle |
US7140371B2 (en) | 2002-03-14 | 2006-11-28 | Allergan, Inc. | Surface topography method for determining effects of a botulinum toxin upon a muscle and for comparing botulinum toxins |
US7691394B2 (en) | 2002-05-28 | 2010-04-06 | Botulinum Toxin Research Associates, Inc. | High-potency botulinum toxin formulations |
US6776991B2 (en) * | 2002-06-26 | 2004-08-17 | Allergan, Inc. | Methods for treating priapism |
AU2003259246A1 (en) * | 2002-07-29 | 2004-02-16 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
US7238357B2 (en) * | 2002-11-05 | 2007-07-03 | Allergan, Inc. | Methods for treating ulcers and gastroesophageal reflux disease |
US20040086532A1 (en) * | 2002-11-05 | 2004-05-06 | Allergan, Inc., | Botulinum toxin formulations for oral administration |
GB2398636A (en) * | 2003-02-21 | 2004-08-25 | Ipsen Ltd | Method for determining the quantity of pre-synaptic neuromuscular blocking substance contained in a sample |
US8071550B2 (en) * | 2003-03-03 | 2011-12-06 | Allergan, Inc. | Methods for treating uterine disorders |
CN1874784B (zh) * | 2003-03-06 | 2010-06-09 | 肉毒素研究同仁股份有限公司 | 用肉毒杆菌毒素治疗鼻窦炎相关的慢性面部疼痛及头痛 |
CA2518155A1 (en) * | 2003-03-06 | 2004-09-16 | Botulinum Toxin Research Associates, Inc. | Treatment of chronic chalazion and hordeolum with botulinum toxin |
US7393538B2 (en) * | 2003-04-25 | 2008-07-01 | Ackerman Alan H | Clostridial toxin treatment for dermatillomania |
US7390496B2 (en) * | 2003-04-25 | 2008-06-24 | Allergan, Inc. | Therapeutic treatments for repetitive hand washing |
US7393537B2 (en) * | 2003-04-25 | 2008-07-01 | Allergan, Inc. | Botulinum toxin for treatment of obsessive compulsive finger biting disorder |
US7396535B2 (en) * | 2003-04-25 | 2008-07-08 | Ackerman Alan H | Therapy for obsessive compulsive head banging |
US7422753B2 (en) * | 2003-04-25 | 2008-09-09 | Allergan, Inc. | Methods for treating trichotillomania |
US6838434B2 (en) * | 2003-05-02 | 2005-01-04 | Allergan, Inc. | Methods for treating sinus headache |
US7220422B2 (en) * | 2003-05-20 | 2007-05-22 | Allergan, Inc. | Methods and compositions for treating eye disorders |
US20040253274A1 (en) * | 2003-06-11 | 2004-12-16 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
US20050013850A1 (en) * | 2003-07-15 | 2005-01-20 | Caers Jan K. | Device to assist hyperhydrosis therapy |
US8734810B2 (en) | 2003-10-29 | 2014-05-27 | Allergan, Inc. | Botulinum toxin treatments of neurological and neuropsychiatric disorders |
US8609113B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8617572B2 (en) * | 2003-10-29 | 2013-12-31 | Allergan, Inc. | Botulinum toxin treatments of depression |
US8609112B2 (en) | 2003-10-29 | 2013-12-17 | Allergan, Inc. | Botulinum toxin treatments of depression |
US20050096550A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transrectal delivery of a denervating agent to the prostate gland |
US20050096549A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transperineal delivery of a denervating agent to the prostate gland |
US20050096629A1 (en) * | 2003-10-31 | 2005-05-05 | Medtronic, Inc. | Techniques for transurethral delivery of a denervating agent to the prostate gland |
US7437194B2 (en) * | 2003-10-31 | 2008-10-14 | Medtronic, Inc. | Stimulating the prostate gland |
US7172764B2 (en) * | 2003-11-17 | 2007-02-06 | Allergan, Inc. | Rescue agents for treating botulinum toxin intoxications |
GB0328060D0 (en) * | 2003-12-04 | 2004-01-07 | Sod Conseils Rech Applic | Botulinum toxin treatment |
US20050129677A1 (en) * | 2003-12-10 | 2005-06-16 | Shengwen Li | Lipid rafts and clostridial toxins |
US20050148935A1 (en) * | 2003-12-29 | 2005-07-07 | Rozalina Dimitrova | Botulinum toxin injection guide |
US9211248B2 (en) | 2004-03-03 | 2015-12-15 | Revance Therapeutics, Inc. | Compositions and methods for topical application and transdermal delivery of botulinum toxins |
EP1824488B1 (en) * | 2004-05-07 | 2017-08-09 | Algenis SpA | Phycotoxins and uses thereof |
BRPI0510760A (pt) * | 2004-05-07 | 2007-11-20 | Phytotox Ltd | método para administrar a um paciente uma composição, composição tópica, e, emplastro |
US8173797B2 (en) * | 2004-07-21 | 2012-05-08 | Cornell Research Foundation, Inc. | Therapeutic compounds derived from spider venom and their method of use |
US20060024794A1 (en) * | 2004-07-30 | 2006-02-02 | Shengwen Li | Novel methods for production of di-chain botulinum toxin |
US20080102090A1 (en) | 2004-08-04 | 2008-05-01 | Naveed Panjwani | Pharmaceutical Compositon Containing Botulinum Neurotoxin A2 |
EP1776137B1 (en) | 2004-08-04 | 2014-11-26 | Ipsen Biopharm Limited | Pharmaceutical composition containing botulinum neurotoxin a2 |
US7429386B2 (en) | 2004-09-03 | 2008-09-30 | Allergan, Inc. | Stretch mark treatment |
US7179474B2 (en) * | 2004-09-03 | 2007-02-20 | Allergan, Inc. | Methods for treating a buttock deformity |
US7727537B2 (en) | 2005-02-14 | 2010-06-01 | Dpm Therapeutics Corp. | Stabilized compositions for topical administration and methods of making same |
JP4913074B2 (ja) | 2005-03-03 | 2012-04-11 | アラーガン、インコーポレイテッド | 動物由来産物不含方法およびボツリヌス毒素を精製するための方法 |
US7419675B2 (en) * | 2005-05-26 | 2008-09-02 | Allergan, Inc. | Method for treating peritoneal adhesions |
US8439867B2 (en) * | 2005-06-07 | 2013-05-14 | David R. Staskin | Injection guidance system and method |
US20070038089A1 (en) * | 2005-06-29 | 2007-02-15 | Olympus Medical Systems Corp. | Transurethral diagnostic method and treatment method using ultrasonic endoscope |
CN103315954A (zh) | 2005-07-18 | 2013-09-25 | 麻萨诸塞州洛厄尔大学 | 制备与使用纳米乳剂的组合物和方法 |
US7910116B2 (en) * | 2005-08-24 | 2011-03-22 | Allergan, Inc. | Use of a botulinum toxin to improve gastric emptying and/or to treat GERD |
JP5815915B2 (ja) * | 2005-10-11 | 2015-11-17 | ユニバーシティー オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケーション | 過活動膀胱障害の治療のためのスフィンゴミエリンリポソーム |
KR20200052989A (ko) | 2005-12-01 | 2020-05-15 | 유니버시티 오브 메사츄세츠 로웰 | 보툴리눔 나노에멀젼 |
US9486408B2 (en) | 2005-12-01 | 2016-11-08 | University Of Massachusetts Lowell | Botulinum nanoemulsions |
US20090312696A1 (en) * | 2005-12-28 | 2009-12-17 | Copa Vincent G | Devices, Systems, and Related Methods for Delivery of Fluid to Tissue |
US7770674B2 (en) * | 2006-03-14 | 2010-08-10 | Fallbrook Technologies Inc. | Wheel chair |
US7794386B2 (en) | 2006-03-15 | 2010-09-14 | Allergan, Inc. | Methods for facilitating weight loss |
US7811586B2 (en) * | 2006-05-02 | 2010-10-12 | Allergan, Inc. | Methods for alleviating testicular pain |
WO2008030638A2 (en) * | 2006-05-16 | 2008-03-13 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
AR061669A1 (es) * | 2006-06-29 | 2008-09-10 | Merz Pharma Gmbh & Co Kgaa | Aplicacion de alta frecuencia de terapia con toxina botulinica |
US10792344B2 (en) | 2006-06-29 | 2020-10-06 | Merz Pharma Gmbh & Co. Kgaa | High frequency application of botulinum toxin therapy |
US20080092910A1 (en) * | 2006-10-18 | 2008-04-24 | Allergan, Inc. | Apparatus and method for treating obesity using neurotoxins in conjunction with bariatric procedures |
US20080113051A1 (en) * | 2006-11-13 | 2008-05-15 | Allergan, Inc. | Methods for alleviating tattoo pain |
CN101848702B (zh) * | 2006-12-01 | 2013-07-17 | 安特里奥公司 | 两亲实体纳米粒子 |
CN107080703A (zh) * | 2006-12-01 | 2017-08-22 | 安特里奥公司 | 肽纳米粒子和其用途 |
EP2583687B1 (en) * | 2007-02-15 | 2014-08-27 | Allergan, Inc. | Use of botulinum toxin for treating hyperhydrosis |
CN101765423B (zh) | 2007-05-31 | 2014-08-06 | 安特里奥公司 | 核酸纳米粒子和其用途 |
KR20100087019A (ko) | 2007-10-23 | 2010-08-02 | 알러간, 인코포레이티드 | 변형 클로스트리듐 독소를 사용한 비뇨생식기-신경학적 질환의 치료 방법 |
US8470337B2 (en) * | 2008-03-13 | 2013-06-25 | Allergan, Inc. | Therapeutic treatments using botulinum neurotoxin |
WO2009158687A1 (en) * | 2008-06-26 | 2009-12-30 | Anterios, Inc. | Dermal delivery |
CA2745657C (en) | 2008-12-04 | 2022-06-21 | Botulinum Toxin Research Associates, Inc. | Extended length botulinum toxin formulation for human or mammalian use |
US8278279B2 (en) * | 2008-12-15 | 2012-10-02 | Protox Therapeutics Corp. | Method for treating prostatitis utilizing modified pore-forming protein proaerolysin |
WO2010078403A2 (en) * | 2008-12-30 | 2010-07-08 | Lipella Pharmaceuticals Inc. | Methods and compositions for diagnosing urological disorders |
US8133491B1 (en) | 2009-01-30 | 2012-03-13 | The University Of Toledo | Compositions and methods for treatment of hyperplastic disorders |
EP2403522B1 (en) | 2009-03-06 | 2015-12-16 | Allergan, Inc. | Clostridial toxin to improve ejaculate |
US8198229B2 (en) | 2009-05-29 | 2012-06-12 | Allergan, Inc. | Methods of treating urogenital-neurological disorders using galanin retargeted endopepidases |
US20100303788A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Galanin Retargeted Endopepidases |
US20100303794A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303756A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Interleukin Retargeted Endopepidases |
US20100303789A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Neurotrophin Retargeted Endopepidases |
US20100303798A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Neurotrophin Retargeted Endopepidases |
US20100303791A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Chronic Neurogenic Inflammation Using Glucagon Like Hormone Retargeted Endopepidases |
US20100303783A1 (en) * | 2009-05-29 | 2010-12-02 | Allergan, Inc. | Methods of Treating Urogenital-Neurological Disorders Using Tachykinin Retargeted Endopepidases |
US8147848B2 (en) | 2009-08-26 | 2012-04-03 | Allergan, Inc. | Method for treating premature ejaculation with a botulinum neurotoxin |
EP2482838A4 (en) | 2009-09-30 | 2013-04-10 | Toxcure Inc | USE OF BOTULINUM NEUROTOXIN FOR THE TREATMENT OF SUBSTANCE DEPENDENCE |
WO2012024269A2 (en) | 2010-08-18 | 2012-02-23 | Medtronic, Inc. | Urgency therapy with neuromodulation and c-afferent nerve desensitization |
EP2672958A1 (en) | 2011-02-08 | 2013-12-18 | Halozyme, Inc. | Composition and lipid formulation of a hyaluronan-degrading enzyme and the use thereof for treatment of benign prostatic hyperplasia |
US20120207733A1 (en) * | 2011-02-14 | 2012-08-16 | Allergan, Inc. | Treating a Disease of Hyperproliferation Using Retargeted Endopeptidases |
US8992941B2 (en) | 2011-07-08 | 2015-03-31 | Allergan, Inc. | Method for treatment of esophageal spasm |
KR20140054028A (ko) | 2011-07-08 | 2014-05-08 | 알러간, 인코포레이티드 | 자율신경계 장애의 치료방법 |
US9144600B2 (en) * | 2011-07-14 | 2015-09-29 | Allergan, Inc. | Methods for treatment of incontinence associated with sexual activity |
US20140127188A1 (en) | 2011-07-20 | 2014-05-08 | Katherine Cernok | Method for treatment of adipose deposits |
US20130171122A1 (en) * | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
RU2635466C2 (ru) * | 2012-04-08 | 2017-11-13 | Теракоат Лтд | Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия |
US9393291B2 (en) | 2012-04-12 | 2016-07-19 | Botulinum Toxin Research Associates, Inc. | Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds |
US10149893B2 (en) | 2013-09-24 | 2018-12-11 | Allergan, Inc. | Methods for modifying progression of osteoarthritis |
US9901627B2 (en) | 2014-07-18 | 2018-02-27 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
US11484580B2 (en) | 2014-07-18 | 2022-11-01 | Revance Therapeutics, Inc. | Topical ocular preparation of botulinum toxin for use in ocular surface disease |
CN107208204B (zh) * | 2015-02-03 | 2021-06-18 | 霍加纳斯股份有限公司 | 用于容易切削加工的粉末金属组合物 |
MA45492A (fr) | 2016-06-23 | 2019-05-01 | Hopitaux Paris Assist Publique | Vecteurs viraux pour le traitement de l'hyperactivité vésicale neurogène |
WO2018038301A1 (en) | 2016-08-26 | 2018-03-01 | Hugel Inc. | Stabilized liquid formulation of botulinum toxin and preparation method thereof |
MX2019002835A (es) | 2016-09-13 | 2019-09-04 | Allergan Inc | Composiciones no proteínicas de toxina clostridial. |
EP3541358A1 (en) | 2016-11-21 | 2019-09-25 | Eirion Therapeutics, Inc. | Transdermal delivery of large agents |
EP3470054B1 (en) | 2017-10-11 | 2023-09-20 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
US10525111B2 (en) | 2017-10-12 | 2020-01-07 | Hugel, Inc. | Microstructure formulation techniques for botulinum toxin |
US10792400B2 (en) | 2017-10-12 | 2020-10-06 | Hugel Inc. | Microstructure formulation techniques for botulinum toxin |
RU2687106C1 (ru) * | 2017-12-19 | 2019-05-07 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ФГБОУ ВО ВолгГМУ МЗ РФ | Способ лечения синдрома гиперактивного мочевого пузыря |
EP3660509B1 (en) | 2018-11-29 | 2022-03-09 | Hugel Inc. | A cell-based method for determining an activity of botulinum toxin |
CN110935009B (zh) * | 2019-12-24 | 2023-07-11 | 云南南诏药业有限公司 | 科博肽制剂在制备治疗痔疮药物中的应用 |
RU2768606C1 (ru) * | 2021-04-16 | 2022-03-24 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр колопроктологии имени А.Н. Рыжих" Министерства здравоохранения Российской Федерации | Способ комбинированного хирургического лечения хронической анальной трещины со спазмом сфинктера методом иссечения трещины в сочетании с инъекцией ботулинического токсина типа А в дозировке 40 ЕД во внутренний анальный сфинктер под ультразвуковой навигацией |
Family Cites Families (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4932936A (en) † | 1988-01-29 | 1990-06-12 | Regents Of The University Of Minnesota | Method and device for pharmacological control of spasticity |
JPH0642950Y2 (ja) * | 1988-10-15 | 1994-11-09 | 株式会社マイコー | ケース固定装置 |
US5919665A (en) | 1989-10-31 | 1999-07-06 | Ophidian Pharmaceuticals, Inc. | Vaccine for clostridium botulinum neurotoxin |
US5183462A (en) | 1990-08-21 | 1993-02-02 | Associated Synapse Biologics | Controlled administration of chemodenervating pharmaceuticals |
US5192751A (en) | 1992-07-24 | 1993-03-09 | Eli Lilly And Company | Use of competitive NMDA receptor antagonists in the treatment of urinary incontinence |
CA2164626C (en) | 1993-06-10 | 2004-11-23 | K. Roger Aoki | Multiple botulinum toxins for treating neuromuscular disorders and conditions |
US5437291A (en) | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
JP3238154B2 (ja) | 1993-12-28 | 2001-12-10 | アラーガン・セイルズ・インコーポレイテッド | 過度の発汗を軽減するためのボツリヌス毒素含有医薬組成物 |
GB9508204D0 (en) | 1995-04-21 | 1995-06-07 | Speywood Lab Ltd | A novel agent able to modify peripheral afferent function |
US5837265A (en) * | 1996-03-08 | 1998-11-17 | The Regents Of The University Of California | Chemically-modified clostridiatoxin with improved properties |
US5939070A (en) | 1996-10-28 | 1999-08-17 | Wisconsin Alumni Research Foundation | Hybrid botulinal neurotoxins |
CA2570406C (en) | 1997-07-15 | 2012-02-14 | The Regents Of The University Of Colorado | Use of botulinum toxin for treating pelvic pain |
US9066943B2 (en) | 1997-07-15 | 2015-06-30 | The Regents Of The University Of Colorado | Use of botulinum toxin therapy for treatment of urological neurological conditions |
US7455845B2 (en) | 1997-07-15 | 2008-11-25 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to lowering elevated bladder pressure |
US7470431B2 (en) | 1997-07-15 | 2008-12-30 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer |
US7449192B2 (en) | 1997-07-15 | 2008-11-11 | The Regents Of The University Of Colorado | Use of neurotoxin therapy for treatment of urologic and related disorders related to neurogenic bladder dysfunction |
JP3655061B2 (ja) * | 1997-07-31 | 2005-06-02 | 株式会社ニデック | 紫外線吸収性基材 |
JP2000214813A (ja) * | 1999-01-22 | 2000-08-04 | Mercury Enterprise:Kk | 二輪及び三輪車輌・トラック・四輪車両へ搭載可能な可動式省エネ広告塔 |
US6306423B1 (en) | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
JP2002132198A (ja) * | 2000-10-25 | 2002-05-09 | Sukenori Kiuchi | 三輪自転車一体型移動式回転広告塔 |
JP2002306290A (ja) * | 2001-04-19 | 2002-10-22 | Takumi:Kk | ターンテーブル |
JP2007037725A (ja) * | 2005-08-02 | 2007-02-15 | Masahiro Matsubara | 多機能立方体展示ユニット |
JP3121792U (ja) * | 2005-10-28 | 2006-06-01 | 株式会社イマジンクリエイション | ラック付3dレンズ使用立体型看板 |
-
1998
- 1998-07-15 CA CA2570406A patent/CA2570406C/en not_active Expired - Lifetime
- 1998-07-15 ES ES05024445.8T patent/ES2336924T5/es not_active Expired - Lifetime
- 1998-07-15 ES ES04019371.6T patent/ES2255025T5/es not_active Expired - Lifetime
- 1998-07-15 AT AT98933345T patent/ATE320815T1/de active
- 1998-07-15 JP JP2000502781A patent/JP3692033B2/ja not_active Expired - Lifetime
- 1998-07-15 ES ES98933345T patent/ES2256945T5/es not_active Expired - Lifetime
- 1998-07-15 DE DE69833942T patent/DE69833942T3/de not_active Expired - Lifetime
- 1998-07-15 AT AT04026167T patent/ATE339220T1/de active
- 1998-07-15 ES ES08154321.7T patent/ES2450747T3/es not_active Expired - Lifetime
- 1998-07-15 DE DE69833059.5T patent/DE69833059T3/de not_active Expired - Lifetime
- 1998-07-15 PT PT04026167T patent/PT1502601E/pt unknown
- 1998-07-15 CA CA002505933A patent/CA2505933C/en not_active Expired - Lifetime
- 1998-07-15 EP EP04026167A patent/EP1502601B2/en not_active Expired - Lifetime
- 1998-07-15 ES ES04026167T patent/ES2268567T5/es not_active Expired - Lifetime
- 1998-07-15 EP EP09175439A patent/EP2145629B1/en not_active Expired - Lifetime
- 1998-07-15 CN CNB2004100962262A patent/CN1321683C/zh not_active Expired - Lifetime
- 1998-07-15 AT AT04019371T patent/ATE314085T1/de active
- 1998-07-15 AU AU83007/98A patent/AU743085B2/en not_active Expired
- 1998-07-15 CN CNB2006101006710A patent/CN100518816C/zh not_active Expired - Lifetime
- 1998-07-15 WO PCT/US1998/014625 patent/WO1999003483A1/en active IP Right Grant
- 1998-07-15 CN CN031104711A patent/CN1480212B/zh not_active Expired - Lifetime
- 1998-07-15 AT AT09175439T patent/ATE552006T1/de active
- 1998-07-15 EP EP98933345A patent/EP1011695B2/en not_active Expired - Lifetime
- 1998-07-15 EP EP05024445.8A patent/EP1658858B2/en not_active Expired - Lifetime
- 1998-07-15 EP EP10169366A patent/EP2246066A1/en not_active Ceased
- 1998-07-15 DK DK09175439.0T patent/DK2145629T3/da active
- 1998-07-15 CN CN2005101138787A patent/CN1803189B/zh not_active Expired - Lifetime
- 1998-07-15 EP EP05024444A patent/EP1637157A1/en not_active Withdrawn
- 1998-07-15 CA CA002505930A patent/CA2505930C/en not_active Expired - Lifetime
- 1998-07-15 CA CA002296720A patent/CA2296720C/en not_active Expired - Lifetime
- 1998-07-15 AT AT05024445T patent/ATE448792T1/de active
- 1998-07-15 CA CA002521392A patent/CA2521392A1/en not_active Abandoned
- 1998-07-15 DE DE69841291T patent/DE69841291D1/de not_active Expired - Lifetime
- 1998-07-15 DK DK04019371.6T patent/DK1475099T4/da active
- 1998-07-15 ES ES09175439T patent/ES2385130T3/es not_active Expired - Lifetime
- 1998-07-15 DK DK08154321.7T patent/DK1949909T3/en active
- 1998-07-15 PT PT09175439T patent/PT2145629E/pt unknown
- 1998-07-15 PT PT81543217T patent/PT1949909E/pt unknown
- 1998-07-15 DK DK04026167.9T patent/DK1502601T4/da active
- 1998-07-15 CN CNB988091291A patent/CN1135988C/zh not_active Expired - Lifetime
- 1998-07-15 KR KR1020007000506A patent/KR100544060B1/ko not_active IP Right Cessation
- 1998-07-15 PT PT05024445T patent/PT1658858E/pt unknown
- 1998-07-15 EP EP08154321.7A patent/EP1949909B1/en not_active Expired - Lifetime
- 1998-07-15 DE DE69835911T patent/DE69835911T3/de not_active Expired - Lifetime
- 1998-07-15 DK DK05024445.8T patent/DK1658858T4/da active
- 1998-07-15 PT PT98933345T patent/PT1011695E/pt unknown
- 1998-07-15 US US09/463,040 patent/US6365164B1/en not_active Expired - Lifetime
- 1998-07-15 EP EP04019371.6A patent/EP1475099B2/en not_active Expired - Lifetime
- 1998-07-15 DK DK98933345.5T patent/DK1011695T4/da active
-
2001
- 2001-10-15 US US09/978,982 patent/US6667041B2/en not_active Expired - Lifetime
-
2003
- 2003-10-14 US US10/685,995 patent/US7001602B2/en not_active Expired - Lifetime
- 2003-12-22 US US10/745,332 patent/US7153514B2/en not_active Expired - Lifetime
-
2004
- 2004-09-08 HK HK04106802.1A patent/HK1064044A1/xx not_active IP Right Cessation
- 2004-09-08 HK HK06100417A patent/HK1080377A1/xx not_active IP Right Cessation
- 2004-09-08 HK HK06112481.5A patent/HK1091750A1/xx not_active IP Right Cessation
- 2004-12-20 JP JP2004367501A patent/JP2005089479A/ja active Pending
- 2004-12-20 JP JP2004367500A patent/JP3955061B2/ja not_active Expired - Lifetime
-
2005
- 2005-03-11 US US11/077,895 patent/US7429387B2/en not_active Expired - Fee Related
- 2005-11-16 AU AU2005234633A patent/AU2005234633C1/en not_active Expired
- 2005-11-16 JP JP2005331664A patent/JP4053559B2/ja not_active Expired - Lifetime
-
2006
- 2006-01-10 JP JP2006002227A patent/JP2006104221A/ja active Pending
- 2006-11-30 CY CY20061101731T patent/CY1105816T1/el unknown
-
2007
- 2007-01-10 JP JP2007002407A patent/JP4696082B2/ja not_active Expired - Lifetime
- 2007-01-10 JP JP2007002406A patent/JP4672676B2/ja not_active Expired - Lifetime
-
2008
- 2008-04-17 JP JP2008107792A patent/JP4815468B2/ja not_active Expired - Lifetime
- 2008-10-09 HK HK08111205.0A patent/HK1119396A1/xx not_active IP Right Cessation
-
2009
- 2009-11-20 JP JP2009264712A patent/JP5005753B2/ja not_active Expired - Lifetime
-
2010
- 2010-02-17 CY CY20101100157T patent/CY1109827T1/el unknown
-
2012
- 2012-05-25 CY CY20121100474T patent/CY1113355T1/el unknown
- 2012-08-03 LU LU92055C patent/LU92055I2/fr unknown
-
2013
- 2013-07-10 LU LU92250C patent/LU92250I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4053559B2 (ja) | 過活動膀胱を治療するための治療剤 | |
US7968104B2 (en) | Use of neurotoxin therapy for treatment of urologic and related disorders | |
AU2008201535C1 (en) | Use of neurotoxin therapy for treatment of urologic and related disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20051118 |
|
A975 | Report on accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A971005 Effective date: 20051226 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060110 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20060410 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20060414 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060706 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20060912 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20061212 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20061215 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070309 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20070515 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070910 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20070921 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20070910 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20071127 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20071205 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20101214 Year of fee payment: 3 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111214 Year of fee payment: 4 |
|
S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
S533 | Written request for registration of change of name |
Free format text: JAPANESE INTERMEDIATE CODE: R313533 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111214 Year of fee payment: 4 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20111214 Year of fee payment: 4 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20121214 Year of fee payment: 5 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20131214 Year of fee payment: 6 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |